Gene signatures of genomic instability as prognostic tools for breast cancer

Bibliography

• 1  Bevers TB, Anderson BO, Bonaccio E et al.: NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J. Natl Compr. Canc. Netw.7,1060–1096 (2009).
  MedlineGoogle Scholar
• 2  Carlson RW, Allred DC, Anderson BO et al.: Breast cancer. Clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw.7,122–192 (2009).
  Medline CASGoogle Scholar
• 3  Azim HA Jr, de Azambuja E, Colozza M, Bines J, Piccart MJ: Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann. Oncol. DOI: 10.1093/annonc/mdq683 (2011) (Epub ahead of print).
  Google Scholar
• 4  Oakman C, Santarpia L, Di Leo A: Breast cancer assessment tools and optimizing adjuvant therapy. Nat. Rev. Clin. Oncol.7,725–732 (2010).
  Medline CASGoogle Scholar
• 5  Subramanian J, Simon R: What should physicians look for in evaluating prognostic gene-expression signatures? Nat. Rev. Clin. Oncol.7,327–334 (2010).
  MedlineGoogle Scholar
• 6  Perou CM, Sorlie T, Eisen MB et al.: Molecular portraits of human breast tumours. Nature406,747–752 (2000).
  Medline CASGoogle Scholar
• 7  Sorlie T, Perou CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98,10869–10874 (2001).
  Medline CASGoogle Scholar
• 8  Sorlie T, Tibshirani R, Parker J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA100,8418–8423 (2003).
  Medline CASGoogle Scholar
• 9  Ellsworth RE, Decewicz DJ, Shriver CD, Ellsworth DL: Breast cancer in the personal genomics era. Curr. Genomics11,146–161 (2010).
  Medline CASGoogle Scholar
• 10  Paik S, Shak S, Tang G et al.: A multigene assay to predict recurrence of tamoxifen treated, node-negative breast cancer. N. Engl. J. Med.351,2817–2826 (2004).
  Medline CASGoogle Scholar
• 11  Paik S, Tang G, Shak S et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol.24,3726–3734 (2006).
  Medline CASGoogle Scholar
• 12  Van’t Veer LJ, Dai H, van de Vijver MJ et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature415,530–536 (2002).
  MedlineGoogle Scholar
• 13  van de Vijver MJ, He YD, van’t Veer LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347,1999–2009 (2002).
  Medline CASGoogle Scholar
• 14  Sotiriou C, Wirapati P, Loi S et al.: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst.98,262–272 (2006).
  Medline CASGoogle Scholar
• 15  Loi S, Haibe-Kains B, Desmedt C et al.: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol.25,1239–1246 (2007).
  Medline CASGoogle Scholar
• 16  Wang Y, Klijn JG, Zhang Y et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet365,671–679 (2005).
  Medline CASGoogle Scholar
• 17  Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ: Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol.26,729–735 (2008).
  MedlineGoogle Scholar
• 18  Zujewski JA, Kamin L: Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol.4,603–610 (2008).
  CASGoogle Scholar
• 19  Fan C, Oh DS, Wessels L et al.: Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med.355,560–569 (2006).
  Medline CASGoogle Scholar
• 20  Chang HY, Sneddon JB, Alizadeh AA et al.: Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol.2,E7 (2004).
  MedlineGoogle Scholar
• 21  Chang HY, Nuyten DS, Sneddon JB et al.: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA102,3738–3743 (2005).
  Medline CASGoogle Scholar
• 22  Liu R, Wang X, Chen GY et al.: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med.356,217–226 (2007).
  Medline CASGoogle Scholar
• 23  Ben-Porath I, Thomson MW, Carey VJ et al.: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet.40,499–507 (2008).
  Medline CASGoogle Scholar
• 24  Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY: Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell2,333–344 (2008).
  Medline CASGoogle Scholar
• 25  Shats I, Gatza ML, Chang JT et al.: Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res.71(5),1772–1780 (2010).
  MedlineGoogle Scholar
• 26  Kronenwett U, Ploner A, Zetterberg A et al.: Genomic instability and prognosis in breast carcinomas. Cancer Epidemiol. Biomarkers Prev.15,1630–1635 (2006).
  Medline CASGoogle Scholar
• 27  Habermann JK, Doering J, Hautaniemi S et al.: The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int. J. Cancer124,1552–1564 (2009).
  Medline CASGoogle Scholar
• 28  Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet.38,1043–1048 (2006).
  Medline CASGoogle Scholar
• 29  Kronenwett U, Huwendiek S, Ostring C et al.: Improved grading of breast adenocarcinomas based on genomic instability. Cancer Res.64,904–909 (2004).
  Medline CASGoogle Scholar
• 30  Chibon F, Lagarde P, Salas S et al.: Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat. Med.16,781–787 (2010).
  Medline CASGoogle Scholar
• 31  Sansregret L, Vadnais C, Livingstone J et al.: Cut homeobox 1 causes chromosomal instability by promoting bipolar division after cytokinesis failure. Proc. Natl Acad. Sci. USA108,1949–1954 (2011).
  Medline CASGoogle Scholar
• 32  De Vos J, Thykjaer T, Tarte K et al.: Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene21,6848–6857 (2002).
  Medline CASGoogle Scholar
• 33  Moon NS, Rong Zeng W, Premdas P, Santaguida M, Berube G, Nepveu A: Expression of N-terminally truncated isoforms of CDP/CUX is increased in human uterine leiomyomas. Int. J. Cancer100,429–432 (2002).
  Medline CASGoogle Scholar
• 34  Ripka S, Neesse A, Riedel J et al.: CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut59,1101–1110 (2010).
  Medline CASGoogle Scholar
• 35  Goulet B, Watson P, Poirier M et al.: Characterization of a tissue-specific CDP/Cux isoform, p75, activated in breast tumor cells. Cancer Res.62,6625–6633 (2002).
  Medline CASGoogle Scholar
• 36  Michl P, Ramjaun AR, Pardo OE et al.: CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness. Cancer Cell7,521–532 (2005).
  Medline CASGoogle Scholar
• 37  Ripka S, Konig A, Buchholz M et al.: WNT5A – target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis28,1178–1187 (2007).
  Medline CASGoogle Scholar
• 38  Aleksic T, Bechtel M, Krndija D et al.: CUTL1 promotes tumor cell migration by decreasing proteasome-mediated Src degradation. Oncogene26,5939–5949 (2007).
  Medline CASGoogle Scholar
• 39  Kedinger V, Sansregret L, Harada R et al.: p110 CUX1 homeodomain protein stimulates cell migration and invasion in part through a regulatory cascade culminating in the repression of E-cadherin and occludin. J. Biol. Chem.284,27701–27711 (2009).
  Medline CASGoogle Scholar
• 40  Cadieux C, Kedinger V, Yao L et al.: Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. Cancer Res.69,7188–7197 (2009).
  Medline CASGoogle Scholar
• 41  Parker JS, Mullins M, Cheang MC et al.: Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol.27,1160–1167 (2009).
  MedlineGoogle Scholar
• 42  Calza S, Hall P, Auer G et al.: Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res.8,R34 (2006).
  MedlineGoogle Scholar
• 43  Hanna W, Nofech-Mozes S, Kahn HJ: Intratumoral heterogeneity of HER2/neu in breast cancer – a rare event. Breast J.13,122–129 (2007).
  Medline CASGoogle Scholar
• 44  Cottu PH, Asselah J, Lae M et al.: Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann. Oncol.19,595–597 (2008).
  Medline CASGoogle Scholar
• 45  Iliopoulos D, Hirsch HA, Wang G, Struhl K: Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl Acad. Sci. USA108,1397–1402 (2011).
  Medline CASGoogle Scholar
• 46  Korkola J, Gray JW: Breast cancer genomes – form and function. Curr. Op. Genet. Dev.20,4–14 (2010).
  Medline CASGoogle Scholar
• 47  Shah SP, Morin RD, Khattra J et al.: Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature461,809–813 (2009).
  Medline CASGoogle Scholar
• 48  Swanton C, Burrell RA, Futreal PA: Breast cancer genome heterogeneity: a challenge to personalised medicine? Breast Cancer Res.13,104 (2011).
  MedlineGoogle Scholar
• 49  Navin N, Krasnitz A, Rodgers L et al.: Inferring tumor progression from genomic heterogeneity. Genome Res.20,68–80 (2010).
  Medline CASGoogle Scholar
• 50  Khalique L, Ayhan A, Whittaker JC et al.: The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int. J. Cancer124,1579–1586 (2009).
  Medline CASGoogle Scholar
• 51  Torres L, Ribeiro FR, Pandis N, Andersen JA, Heim S, Teixeira MR: Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res. Treat.102,143–155 (2007).
  MedlineGoogle Scholar
• 52  Yachida S, Jones S, Bozic I et al.: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature467,1114–1117 (2010).
  Medline CASGoogle Scholar
• 53  Campbell PJ, Yachida S, Mudie LJ et al.: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature467,1109–1113 (2010).
  Medline CASGoogle Scholar
• 54  Storchova Z, Kuffer C: The consequences of tetraploidy and aneuploidy. J. Cell Sci.121,3859–3866 (2008).
  Medline CASGoogle Scholar
• 55  Kronenwett U, Huwendiek S, Castro J, Ried T, Auer G: Characterisation of breast fine-needle aspiration biopsies by centrosome aberrations and genomic instability. Br. J. Cancer92,389–395 (2005).
  Medline CASGoogle Scholar
• 56  Nigg EA: origins and consequences of centrosome aberrations in human cancers. Int. J. Cancer119,2717–2723 (2006).
  Medline CASGoogle Scholar
• 57  Ganem NJ, Godinho SA, Pellman D: A mechanism linking extra centrosomes to chromosomal instability. Nature460,278–282 (2009).
  Medline CASGoogle Scholar
• 58  Kwon M, Godinho SA, Chandhok NS et al.: Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev.22,2189–2203 (2008).
  Medline CASGoogle Scholar
• 59  Thompson SL, Compton DA: Examining the link between chromosomal instability and aneuploidy in human cells. J. Cell Biol.180,665–672 (2008).
  Medline CASGoogle Scholar